Strategic partnerships TILT has established collaboration with Merck and ongoing clinical programs across multiple Phase I trials, indicating a strong openness to partnering with big pharma and academic groups for joint development and commercialization.

US footprint Expansion to Boston signals a focused push in the US for clinical development, partnerships and fundraising, presenting a near-term entry point for US-based collaborations and BD discussions.

Funding runway With total funding of around $73M and recent $2M DoD grant, there is meaningful financial backing to support joint development deals, co-investment opportunities, and milestone-driven partnerships.

Clinical stage assets Lead program TILT-123 is in multiple Phase I trials, offering a tangible co-development target for access to immunotherapy pipelines combining oncolytic virotherapy with TILs, CAR T, or checkpoint inhibitors.

Global reach Finland-based origin with US expansion and international funding highlights potential for multi-region trials, cross-border licensing, and regional strategic alliances to accelerate global commercialization.